ADAP vs. ATYR, ATAI, ACB, AQST, CMPX, DBVT, CRVS, IMMP, RNAC, and AURA
Should you be buying Adaptimmune Therapeutics stock or one of its competitors? The main competitors of Adaptimmune Therapeutics include Atyr PHARMA (ATYR), Atai Life Sciences (ATAI), Aurora Cannabis (ACB), Aquestive Therapeutics (AQST), Compass Therapeutics (CMPX), DBV Technologies (DBVT), Corvus Pharmaceuticals (CRVS), Immutep (IMMP), Cartesian Therapeutics (RNAC), and Aura Biosciences (AURA). These companies are all part of the "pharmaceutical products" industry.
Adaptimmune Therapeutics vs.
Adaptimmune Therapeutics (NASDAQ:ADAP) and Atyr PHARMA (NASDAQ:ATYR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation, community ranking and profitability.
In the previous week, Adaptimmune Therapeutics had 6 more articles in the media than Atyr PHARMA. MarketBeat recorded 16 mentions for Adaptimmune Therapeutics and 10 mentions for Atyr PHARMA. Atyr PHARMA's average media sentiment score of 0.81 beat Adaptimmune Therapeutics' score of 0.11 indicating that Atyr PHARMA is being referred to more favorably in the news media.
Atyr PHARMA has a net margin of 0.00% compared to Adaptimmune Therapeutics' net margin of -25.43%. Adaptimmune Therapeutics' return on equity of -74.15% beat Atyr PHARMA's return on equity.
Adaptimmune Therapeutics received 315 more outperform votes than Atyr PHARMA when rated by MarketBeat users. However, 100.00% of users gave Atyr PHARMA an outperform vote while only 63.39% of users gave Adaptimmune Therapeutics an outperform vote.
Atyr PHARMA has lower revenue, but higher earnings than Adaptimmune Therapeutics. Atyr PHARMA is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.
Adaptimmune Therapeutics presently has a consensus target price of $1.52, indicating a potential upside of 452.12%. Atyr PHARMA has a consensus target price of $18.60, indicating a potential upside of 396.00%. Given Adaptimmune Therapeutics' higher probable upside, equities research analysts clearly believe Adaptimmune Therapeutics is more favorable than Atyr PHARMA.
31.4% of Adaptimmune Therapeutics shares are held by institutional investors. Comparatively, 61.7% of Atyr PHARMA shares are held by institutional investors. 12.7% of Adaptimmune Therapeutics shares are held by insiders. Comparatively, 3.7% of Atyr PHARMA shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Adaptimmune Therapeutics has a beta of 2.86, meaning that its stock price is 186% more volatile than the S&P 500. Comparatively, Atyr PHARMA has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.
Summary
Adaptimmune Therapeutics beats Atyr PHARMA on 10 of the 19 factors compared between the two stocks.
Get Adaptimmune Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adaptimmune Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ADAP) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy ADAP Stock Free ADAP Stock Alerts